Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Enroll save search
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
Published: 2023-06-07 (Crawled : 12:00) - globenewswire.com
LIXT | $3.351 4.68% 11K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -9.42%
lb-100 group enroll trial doxorubicin
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
Published: 2023-02-08 (Crawled : 14:20) - prnewswire.com
NRSN | News | $1.435 -5.59% -5.92% 120K
|
|
| O: -0.65%
H: 23.68%
C: 0.0%
enroll als trial approval germany
Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial
Published: 2022-11-11 (Crawled : 14:00) - biospace.com/
IMMX | News | $2.21 0.0% 64K
|
|
| O: 13.33%
H: 5.88%
C: 2.94%
imx-110 biopharma enroll trial approval review
Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher
Published: 2022-11-11 (Crawled : 13:20) - globenewswire.com
IMMX | News | $2.21 0.0% 64K
|
|
| O: 13.33%
H: 5.88%
C: 2.94%
imx-110 biopharma rare drug enroll disease approval review food
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.5 4.65% 4.44% 1.3K
|
Health Technology
|
| O: 2.54%
H: 4.77%
C: -3.24%
trial enroll phase 3
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.5%
H: 2.01%
C: 1.79%
hzn-7734 treatment trial therapeutics enroll phase 2
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Acutus Medical completes enrollment in IDE trial with its AcQBlate® FORCE Sensing Ablation System
Published: 2022-05-13 (Crawled : 19:00) - biospace.com/
AFIB | $0.167 -4.3% -4.49% 400K
|
Health Technology
|
| O: 5.19%
H: 0.0%
C: -10.31%
acqblate system trial enroll
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K
|
Manufacturing
|
| O: 0.46%
H: 1.84%
C: -9.68%
trial therapeutics enroll
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: -0.3%
H: 4.07%
C: -4.72%
enroll phase 2
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: -1.04%
H: 14.36%
C: 3.87%
skinte drug diabetic enroll
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
Published: 2022-04-29 (Crawled : 13:00) - biospace.com/
CTSO | $0.8026 0.2% 0.2% 46K
|
Health Technology
|
| O: 6.46%
H: 0.0%
C: 0.0%
system trial enroll
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
VAXX | $0.4761 2.43% 2.37% 290K
|
|
| O: -1.94%
H: 8.76%
C: 6.5%
ub-312 disease trial enroll phase 1
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
ABVC | News | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 0.87%
H: 2.16%
C: 2.16%
biopharma adhd enroll
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
Published: 2022-04-26 (Crawled : 18:00) - globenewswire.com
GLTO | $0.72 4.71% 77K
|
Health Technology
|
| O: 0.53%
H: 1.58%
C: -8.42%
gb0139 treatment trial enroll phase 2b
Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
RMTI | $1.46 -1.35% -1.37% 82K
|
Health Technology
|
| O: 0.0%
H: 1.43%
C: -2.09%
triferic trial china enroll phase 3
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
Published: 2022-04-25 (Crawled : 13:20) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: -3.12%
H: 2.86%
C: 0.0%
trial cancer enroll
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Published: 2022-04-20 (Crawled : 12:20) - biospace.com/
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: 1.22%
H: 0.84%
C: -0.74%
fibrosis enroll phase 3
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
Published: 2022-04-19 (Crawled : 13:20) - prnewswire.com
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 2.92%
H: 0.0%
C: -8.37%
disease trial alzheimer's enroll alzheimer’s phase 2b
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
Published: 2022-04-14 (Crawled : 13:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: -0.23%
H: 7.18%
C: 2.59%
trial enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.